<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FDE5D219-3C33-4D20-AE5F-C8E3CB22088A"><gtr:id>FDE5D219-3C33-4D20-AE5F-C8E3CB22088A</gtr:id><gtr:firstName>Donald</gtr:firstName><gtr:surname>Davidson</gtr:surname><gtr:orcidId>0000-0002-8782-199X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002046"><gtr:id>E3137F7A-3C7B-4F72-82D5-F619775ACE80</gtr:id><gtr:title>Cathelicidins as immunomodulators of host defence against infectious diseases</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002046</gtr:grantReference><gtr:abstractText>Lung diseases are among the most common causes of ill-heath, accounting for 20% of deaths in the UK, with one third due to infectious diseases. The rise of superbugs is a ever increasing challenge, urgently requiring new treatments and a greater understanding of the body?s natural protective mechanisms.

Important components of our body?s early defence system are cationic host-defence peptides (CHDP). Initially studied for their ability to kill bacteria and viruses, we have discovered many ways in which CHDP can alter inflammation, modulating the body?s response to threat and damage, and the repair systems. CHDP are therefore drug templates with the capacity to kill microbes and enhance our natural protective responses. CHDP also offer the potential to circumvent the strategies that make superbugs resistant to our current conventional treatments.

Building upon the foundation I have established with my recent research, I propose to: 1) determine the cellular pathways involved in the key activities of CHDP (particularly regulating the responses of airway lining cells to infection), 2) determine the role of these activities in protecting against the establishment of infection, and 3) design novel CHDP as potential therapeutics, with a particular focus on the treatment of pathogenic lung viruses, including influenza.</gtr:abstractText><gtr:technicalSummary>Respiratory diseases are among the most common causes of morbidity, and account for one in five deaths in the UK, with one third due to acute respiratory infections, influenza or pneumonia. Pathogens resistant to conventional treatments represent an growing challenge. Greater understanding of natural protective mechanisms and novel treatments are urgently required.

Innate responses are the first line of defence, but remain under-researched and under-exploited. Important components of early innate immunity are cationic host-defence peptides (CHDP; e.g., cathelicidins). Initially described as directly microbicidal agents, we have discovered multiple roles for CHDP as modulators of inflammation and immunity; thus, they represent exciting templates for novel therapeutics with the capacity to circumvent existing microbial resistance strategies. Although clearly important in health and disease, their specific roles in defence against infectious diseases remain poorly understood.

 The central tenet of this proposal is that the full potential of CHDP-derived antimicrobial therapeutics is only likely to be realised through greater understanding of the multiple mechanisms employed by naturally-occurring CHDP in host defence against specific bacterial and viral infectious diseases. 

 Building upon the foundation I established during my Research Career Development Fellowship, I intend to address the central hypothesis that cathelicidins are key components of innate host defence against infection, that they mediate a recently-described pro-inflammatory caspase 1-dependent cell death (pyroptosis) of infected epithelial cells, with protective innate and adaptive immune consequences, and that cathelicidins represent promising templates for novel microbicidal immunomodulatory strategies for drug-resistant bacteria and viruses.

 I propose to: 1) determine the mechanisms and significance of cathelicidin-mediated pyroptosis of airway epithelial cells infected with invasive bacteria or viruses, and investigate the role of the inflammasome and caspase 1 (including using infection models in vitro and in vivo, live-cell confocal imaging, state-of-the-art in vivo imaging and proteomic analyses); 2) establish the adaptive immune consequences of dendritic cell interaction with infected epithelial cells previously induced to undergo cathelicidin-mediated pyroptosis (including using influenza and Pseudomonas aeruginosa infection models and mutant recombinant virus); and 3) determine the antiviral activities of cathelicidins against respiratory viral pathogens, and the potential for peptide modification in therapeutics (including the use of influenza and respiratory syncytial virus infection models in vitro and in vivo, cryo-electron microscopy and the design of novel CHDP).

 This research will elucidate new roles of CHDP in infectious lung disease, and enable development of a novel innate immunity-based strategy with application for viral and bacterial infections at epithelial surfaces.</gtr:technicalSummary><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1894562</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centers for Disease Control and Prevention (CDC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Influenza Division</gtr:department><gtr:description>CIR - CDC</gtr:description><gtr:id>48DE24F3-7D55-40CD-9744-EA582589F4BD</gtr:id><gtr:impact>Barlow et al 2011 paper in PLoS One.
Studies being further developed in my lab.</gtr:impact><gtr:outcomeId>gCRNiyP3oYm-1</gtr:outcomeId><gtr:partnerContribution>Conducted in vivo studies demonstrating anti-influenza properties of cathelicidins in mice.</gtr:partnerContribution><gtr:piContribution>Established anti-influenza properties of cathelicidins in vitro and co-directed in vivo studies which were conducted at CDC Atlanta.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Illustration and development of &quot;MicroMania&quot; an infectious diseases Happy Families card game for school children.</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F5D750FA-149C-4D3D-A6BC-1009D67F8B9F</gtr:id><gtr:impact>Development and illustration of an educational scientific children's game about infectious diseases, based on Happy Families. 


An educational card game was produced, launched at the British Society for Immunology Congress in December 2011, and now freely available through the BSI. It has been used in a range of public engagement activities and well received by schools.</gtr:impact><gtr:outcomeId>FVHLMmxC8Un</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>https://www.immunology.org/sslpage.aspx?pid=1844</gtr:url><gtr:year>2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh International Science Festival 2014 - 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>26EFDFCC-00C6-4877-8A2B-8BC7ED2D4FB3</gtr:id><gtr:impact>In 2014, over 2000 visitors came to this drop-in event at the National Museum of Scotland from 15th - 19th April, participating in our new learning activities and discussing science with the volunteers. 
In 2015 I ran a sell-out series of workshops for children aged 6 - 11 (120 places) entitled Amazing Immunology
In 2016 we repeated a sell-out series of workshops for children aged 6 - 11 (100 places) entitled Amazing Immunology

The MRC Centre for Inflammation Research has been asked to contribute to the Edinburgh International Science Festival again in 2015 and to the Midlothian Science Festival in 2015. An article on the event was requested for Immunology News.</gtr:impact><gtr:outcomeId>543f93a3ae85c5.30720619</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ed.ac.uk/inflammation-research/information-public/past-public-events/cir-edinburgh-science-festival-2016</gtr:url><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Primary School outreach visits - Science Week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DF865C0C-D32D-41CC-AA3E-E88F7483B337</gtr:id><gtr:impact>I have run a series of self-designed interactive sessions (1 - 3 hours each), on microbiology, immunology and general scientific approaches at East Linton Primary School as a component of their Science weeks, for primary 2 - 6 children.

School asked for further future events and MRC Centre asked to consider broader use of this and other similar events in other schools.</gtr:impact><gtr:outcomeId>RBTAbw5xZiK</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.djdavidsonlab.net/cms/?p=1811&amp;paged=4</gtr:url><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Festival of Medical Research 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6F138E19-EB27-432D-954D-000CD222D4B2</gtr:id><gtr:impact>We develop and new educational games, animations and schools resource on immunology and inflammation and trialled this in 4 schools in the region, with ~ 80 pupils. This provided excellent interaction, new links with schools and invaluable feedback for the next phase of development of this resource.</gtr:impact><gtr:outcomeId>58aac3a439b980.21312804</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.ed.ac.uk/inflammation-research/information-public/past-public-events/mrc-festival-of-medical-research</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>&quot;Going Viral&quot; SciArt Public Engagement initiative</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5F1DDA4D-878D-459F-B951-03DDCCE7C16B</gtr:id><gtr:impact>&amp;quot;Going Viral&amp;quot; was a British Society for Immunology funded art-science collaborative programme of work undertaken by 6 artists and 4 immunologists. I was invited to bring my knowledge of immunology to help advise and inspire the artists in this joint exploration of key functions of our immune system.

Going Viral artists produced artworks that consider, question, interpret and present the immunology they have researched. These were launched with the start of the European Congress for Immunology 2012, at the Glasgow Science Centre, who gave a major space to host the exhibition (6th Sept - 21st Oct 2012).
Press coverage: New Scientist</gtr:impact><gtr:outcomeId>sN4k8e39MeC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.facebook.com/bsigoingviral</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Debating Matters</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9E5D2A6E-34ED-4A9F-AEEA-0567E1C0DFB3</gtr:id><gtr:impact>I was a Judge at a regional Rounds of the schools Debating Matters scheme.

n/a</gtr:impact><gtr:outcomeId>UB8NW6Ye8Qv</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.debatingmatters.com</gtr:url><gtr:year>2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National television, international &amp; national radio, and national newspaper interviews, with additional widespread coverage of press release relating to new publication on Atopic dermatitis</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CAEBC38F-9143-4E5E-82D2-040CAE5754F3</gtr:id><gtr:impact>Following our press release (detailing our new publication on Atopic dermatitis in Journal of Investigative Dermatology) I was interviewed on the topic for prime time Scottish television news (BBC and STV), international (BBC World service) &amp;amp; national (BBC Five Live, Radio Scotland) radio, and national newspaper (Scotsman), with additional widespread coverage in all the major newspapers in the UK (and many internationally) and news websites. I was also interviewed by a local student newspaper and a specialty patient group website. In addition to widespread dissemination of our research findings, I subsequently had many approaches from patients and their relatives (by phone, e-mail and letter); seeking information and advice and offering to participate in future trials arising from this line of research.</gtr:impact><gtr:outcomeId>58aac5a6ca5ca6.92487199</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>https://www.altmetric.com/details/12483351#score</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3914</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Edinburgh Dermatology Research Fund</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>University of Edinburgh</gtr:fundingOrg><gtr:id>2E8ED16E-1D53-4DF3-8D29-38489EAD1596</gtr:id><gtr:outcomeId>543f8eb748f8c4.47665662</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>79DDBE22-DAFD-4A04-A8DF-C36F27BB03DC</gtr:id><gtr:title>Antiviral potential of cathelicidins.</gtr:title><gtr:parentPublicationTitle>Future microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c262b4f3642340a002317756616d68ad"><gtr:id>c262b4f3642340a002317756616d68ad</gtr:id><gtr:otherNames>Barlow PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1746-0913</gtr:issn><gtr:outcomeId>5433e9a149c2e2.80766200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FFE3426-011A-47F6-A8A8-7F908D9C107C</gtr:id><gtr:title>RNA:DNA hybrids are a novel molecular pattern sensed by TLR9.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c76e2116fa9d1c79a6e53bc777fc701"><gtr:id>2c76e2116fa9d1c79a6e53bc777fc701</gtr:id><gtr:otherNames>Rigby RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>pm_540e177e1770c34a5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9DF3323-071B-4127-B11E-DBB1A818AFAC</gtr:id><gtr:title>Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92319dcc0dd9497cd4b579b4d0ce35fc"><gtr:id>92319dcc0dd9497cd4b579b4d0ce35fc</gtr:id><gtr:otherNames>Gray RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5a748d33b76cb7.15287255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0F859B8-A661-4B83-8E9D-6003782B99CA</gtr:id><gtr:title>Antimicrobial protein and Peptide concentrations and activity in human breast milk consumed by preterm infants at risk of late-onset neonatal sepsis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54f5e9330257674fbb86458f3b907e7a"><gtr:id>54f5e9330257674fbb86458f3b907e7a</gtr:id><gtr:otherNames>Trend S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>55015653c04340.97194783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E87728B-E357-4B64-8D40-6E01EE4C84F6</gtr:id><gtr:title>Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps.</gtr:title><gtr:parentPublicationTitle>Journal of inflammation (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92319dcc0dd9497cd4b579b4d0ce35fc"><gtr:id>92319dcc0dd9497cd4b579b4d0ce35fc</gtr:id><gtr:otherNames>Gray RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1476-9255</gtr:issn><gtr:outcomeId>pm_14597_27_23514610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93C74A66-C42A-4329-8EBD-9D961C215DE7</gtr:id><gtr:title>Cell-free fetal DNA and spontaneous preterm birth.</gtr:title><gtr:parentPublicationTitle>Reproduction (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1cd07236f9cc422510df86e26e9f6769"><gtr:id>1cd07236f9cc422510df86e26e9f6769</gtr:id><gtr:otherNames>van Boeckel SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1470-1626</gtr:issn><gtr:outcomeId>5a748d5a2142f2.30568146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64BD7541-D5B6-4974-A392-55C331EDC96A</gtr:id><gtr:title>The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de0af521e3b8927456e4486709e4349d"><gtr:id>de0af521e3b8927456e4486709e4349d</gtr:id><gtr:otherNames>Currie SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14597_27_24023689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EF270AB-ACDB-4F9C-BF34-7FFB4BF6FDB7</gtr:id><gtr:title>A randomized controlled trial of peripheral blood mononuclear cell depletion in experimental human lung inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc797cd3a172aa8fe324b25328d15fb5"><gtr:id>dc797cd3a172aa8fe324b25328d15fb5</gtr:id><gtr:otherNames>Barr LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_14597_27_23627345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68DCF239-25EE-4B85-A4E0-8F15B6A1FE46</gtr:id><gtr:title>Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/061728e954936057e81d0ead8c034920"><gtr:id>061728e954936057e81d0ead8c034920</gtr:id><gtr:otherNames>McFarlane AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58aac0880066c5.51308024</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97447E24-9E5E-4894-B4F9-5CF22B4C7DE0</gtr:id><gtr:title>Cationic host defence peptides: potential as antiviral therapeutics.</gtr:title><gtr:parentPublicationTitle>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dc28afd332af329245e95f98cb94c01"><gtr:id>2dc28afd332af329245e95f98cb94c01</gtr:id><gtr:otherNames>Gwyer Findlay E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1173-8804</gtr:issn><gtr:outcomeId>pm_14597_27_23649937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FFECFE8-F749-4D97-A04B-02CF550E14B5</gtr:id><gtr:title>Human cathelicidin production by the cervix.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69fc8a53053f1317207435e1890bdbaa"><gtr:id>69fc8a53053f1317207435e1890bdbaa</gtr:id><gtr:otherNames>Frew L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54292cc8c5e1d1.90806277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAB5D7EA-903E-43FA-9F60-8FE8FBE51917</gtr:id><gtr:title>Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c262b4f3642340a002317756616d68ad"><gtr:id>c262b4f3642340a002317756616d68ad</gtr:id><gtr:otherNames>Barlow PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14597_27_22031815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8074373E-E028-430D-B4BF-2B99E2E6D462</gtr:id><gtr:title>Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/903db3e2d28bdd3cef30d4206a136bab"><gtr:id>903db3e2d28bdd3cef30d4206a136bab</gtr:id><gtr:otherNames>Beaumont PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54292cc8985d12.37259091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0877EEB-DF52-4BE6-8B73-D4133180291A</gtr:id><gtr:title>IL-1?-Induced Protection of Keratinocytes against Staphylococcus aureus-Secreted Proteases Is Mediated by Human ?-Defensin 2.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bfd09e5279e3a5a684b4d3321e04515"><gtr:id>9bfd09e5279e3a5a684b4d3321e04515</gtr:id><gtr:otherNames>Wang B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>588b6fe07efe13.97605913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2BB2107-A8D6-4CD5-B68D-BBDBAE0EAFE7</gtr:id><gtr:title>Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b9e67afbae3ddc55d4826e16560961d"><gtr:id>5b9e67afbae3ddc55d4826e16560961d</gtr:id><gtr:otherNames>Thevaranjan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>5a748d0ee1b306.46890830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A049795-D660-4718-993B-7435C7CD2958</gtr:id><gtr:title>Monocytes control second-phase neutrophil emigration in established lipopolysaccharide-induced murine lung injury.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8ce3ba620de702c23f727037840690f"><gtr:id>b8ce3ba620de702c23f727037840690f</gtr:id><gtr:otherNames>Dhaliwal K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_14597_27_22822022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4B69DFB-1102-44D8-AE3D-87E6D620AEFC</gtr:id><gtr:title>Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1838bc97f7415dab93171128fab5c33c"><gtr:id>1838bc97f7415dab93171128fab5c33c</gtr:id><gtr:otherNames>Mandal P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>54292cc861aa39.67751979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97FE8866-6863-42A6-B1DD-5EB7B29ACC8D</gtr:id><gtr:title>Combined dysfunctions of immune cells predict nosocomial infection in critically ill patients.</gtr:title><gtr:parentPublicationTitle>British journal of anaesthesia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7f730c06e18455fc8fcea0cdb66c2d"><gtr:id>6d7f730c06e18455fc8fcea0cdb66c2d</gtr:id><gtr:otherNames>Conway Morris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0912</gtr:issn><gtr:outcomeId>pm_14597_27_23756248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>024D052A-842A-45F0-A344-789366815F2A</gtr:id><gtr:title>Human ?-defensin 3 increases the TLR9-dependent response to bacterial DNA.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/474c47efa59a36b5b24ca8917292254b"><gtr:id>474c47efa59a36b5b24ca8917292254b</gtr:id><gtr:otherNames>McGlasson SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>58aac087ccb3b2.12837457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD272DA4-EB34-46ED-939D-AAB0A02A02DB</gtr:id><gtr:title>Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de0af521e3b8927456e4486709e4349d"><gtr:id>de0af521e3b8927456e4486709e4349d</gtr:id><gtr:otherNames>Currie SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56d81135a29477.92315420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9E0C4D1-4FED-4C23-B36F-558568A6A376</gtr:id><gtr:title>Differential response to bacteria, and TOLLIP expression, in the human respiratory tract.</gtr:title><gtr:parentPublicationTitle>BMJ open respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee408bba342dd4a947cf503567e1cbe5"><gtr:id>ee408bba342dd4a947cf503567e1cbe5</gtr:id><gtr:otherNames>Moncayo-Nieto OL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2052-4439</gtr:issn><gtr:outcomeId>54292f373ce608.85016670</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F8A3C97-DF33-429A-B042-629FD18F6198</gtr:id><gtr:title>Antimicrobial Peptides and Innate Immunity</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/153c67b7af7b31d5a012b251fa87ef47"><gtr:id>153c67b7af7b31d5a012b251fa87ef47</gtr:id><gtr:otherNames>Beaumont P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>3034805403</gtr:isbn><gtr:outcomeId>VEcqRHaPixW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CB16CDB-F1A2-4954-A3B2-7AD3274C32D3</gtr:id><gtr:title>Molecular Medical Microbiology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7dbffd8a98938eec19367aafdad6cbb"><gtr:id>a7dbffd8a98938eec19367aafdad6cbb</gtr:id><gtr:otherNames>Dorin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>9780123971692</gtr:isbn><gtr:outcomeId>56ba048dae60a0.76606361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6119DDA5-9EDF-48EA-84AA-EA8FBCB385DC</gtr:id><gtr:title>Human ?-Defensin 3 [corrected] Exacerbates MDA5 but Suppresses TLR3 Responses to the Viral Molecular Pattern Mimic Polyinosinic:Polycytidylic Acid.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d714c170d2d65f5da61949c860cf1e4"><gtr:id>7d714c170d2d65f5da61949c860cf1e4</gtr:id><gtr:otherNames>Semple F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>56ba02a705c5d0.41608725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B692D0B-730B-4301-89F6-15C3D7DEED1A</gtr:id><gtr:title>A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bb384f7c16edcd7e81f14cb0a13a429"><gtr:id>3bb384f7c16edcd7e81f14cb0a13a429</gtr:id><gtr:otherNames>Bedi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>5a93dad606d6a5.96347264</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002046</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>